Eli Lilly has reported positive results from the head-to-head Phase IV IXORA-R clinical trial, where the company’s Taltz (ixekizumab) demonstrated superiority over Janssen’s Tremfya in plaque psoriasis.

Taltz is an IL-17A inhibitor, while Tremfya blocks IL-23/p19. The IXORA-R study compared the safety and efficacy of the drugs in 1,027 patients with moderate to severe plaque psoriasis.

The trial’s primary endpoint was the proportion of patients with Psoriasis Area Severity Index (PASI) 100 response at week 12.

The endpoint was met, with 41.3% of participants treated with Taltz experiencing complete skin clearance (PASI 100) at week 12 compared to 24.9% of those on Tremfya.

Lilly added that its drug also met all major secondary endpoints.

The trial’s major secondary endpoints include the proportion of patients with PASI 100 at weeks 4, 8 and 24, PASI 90 at weeks 4 and 8, PASI 75 at week 2, PASI 50 at week 1, as well as static Physician’s Global Assessment (sPGA) 0 at week 12.

Lilly immunology global brand development leader Rhonda Pacheco said: “As new medicines become available for people living with psoriasis, there’s an increasing need to directly compare the efficacy and safety of these treatments to help healthcare providers and patients make informed treatment decisions.

“These results demonstrate that Taltz can provide high levels of skin clearance early in treatment for people with psoriasis.”

Results further showed that the safety profiles of both the drugs were consistent with their previous data. The Phase IV IXORA-R trial is ongoing.

The data on the remaining key secondary endpoint of the proportion of patients with PASI 100 at week 24 is expected to be reported next year.